Point-of-care Coagulation Monitoring: Current Status of Viscoelastic Techniques
Hemostasis monitoring is becoming increasingly important in the management of bleeding patients in the operating room (OR) and the intensive care unit (ICU) in order to improve outcome and reduce costs of treatment. It has been shown in cardiac surgery that frequent reassessment of the coagulation status and transfusion according to well-structured algorithms reduced blood loss and blood component use when compared with transfusion regimens based on clinician discretion [1, 2]. Routine laboratory based coagulation tests (e.g., prothrombin time [PT]/interna-tional normalized ratio [INR], activated partial thromboplastin time [aPTT], fibrin-ogen) measure clotting times and factors in recalcified plasma after activation with different coagulation activators. Platelet numbers are given to complete overall coagulation assessment. Although the values obtained by routine coagulation testing are accurate, standardized, and have been used for a long time, their use has been questioned in the assessment of a severely bleeding patient because values are measured in plasma, no information on platelet function is available, and there is a time delay of 30–60 min from sampling to obtaining the results.
KeywordsPlatelet Function Orthotopic Liver Transplantation Fibrin Formation Whole Blood Coagulation Status
Unable to display preview. Download preview PDF.
- 5.von Kaulla KN, Ostendorf P, von Kaulla E (1975) The impedance machine: a new bedside coagulation recording device. J Med 6:73–88Google Scholar
- 40.Coppell JA, Thalheimer U, Zambruni A, et al (2006) The effects of unfractionated heparin, low molecular weight heparin and danaparoid on the thromboelastogram (TEG): an in-vitro comparison of standard and heparinase-modified TEGs with conventional coagulation assays. Blood Coagul Fibrinolysis 17:97–104PubMedCrossRefGoogle Scholar
- 46.Ganter MT, Schmuck S, Hamiel CR, Zollinger A, Hofer CK (2006) Monitoring the effects of factor VIIa treatment in-vitro after severe hemodilution (part I — Sonoclot). Anesthesiology 105(Suppl):A1005 (abst)Google Scholar
- 49.Schmuck S, Ganter MT, Hamiel CR, Zollinger A, Hofer CK (2006) Monitoring the effects of factor VIIa treatment in-vitro after severe hemodilution (part II — ROTEM). Anesthesiology 105(Suppl):A1001 (abst)Google Scholar